Phosphorylated tau at T181, T217, and T205 residues were detected in the CSF of AD patients, and the levels of phosphorylated tau increased during the disease progression, positively correlating with neuronal dysfunction (Fagan et al., 2007; Barthélemy et al., 2020). This evidence concerns the gene MAPT and Alzheimer disease.